This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (199)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Review  • Adverse Effects  • Alert me on articles by topic

A Systematic Review

Kathryn A. Phillips, PhD; David L. Veenstra, PhD, PharmD; Eyal Oren, BA; Jane K. Lee, BA; Wolfgang Sadee, PhD

JAMA. 2001;286:2270-2279.

Context  Adverse drug reactions are a significant cause of morbidity and mortality. Although many adverse drug reactions are considered nonpreventable, recent developments suggest these reactions may be avoided through individualization of drug therapies based on genetic information, an application known as pharmacogenomics.

Objective  To evaluate the potential role of pharmacogenomics in reducing the incidence of adverse drug reactions.

Data Sources  MEDLINE English-language only searches for adverse drug reaction studies published between January 1995 and June 2000 and review articles of variant alleles of drug-metabolizing enzymes published between January 1997 and August 2000. We also used online resources, texts, and expert opinion.

Study Selection  Detailed inclusion criteria were used to select studies. We included 18 of 333 adverse drug reaction studies and 22 of 61 variant allele review articles.

Data Extraction  All the investigators reviewed and coded articles using standardized abstracting forms.

Data Synthesis  We identified 27 drugs frequently cited in adverse drug reaction studies. Among these drugs, 59% are metabolized by at least 1 enzyme with a variant allele known to cause poor metabolism. Conversely, only 7% to 22% of randomly selected drugs are known to be metabolized by enzymes with this genetic variability (range, P = .006-P<.001).

Conclusions  Our results suggest that drug therapy based on individuals' genetic makeups may result in a clinically important reduction in adverse outcomes. Our findings serve as a foundation for further research on how pharmacogenomics can reduce the incidence of adverse reactions and on the resulting clinical, societal, and economic implications.

Author Affiliations: Department of Clinical Pharmacy (Drs Phillips, Mr Oren, and Ms Lee) and Biopharmaceutics (Dr Sadee) University of California-San Francisco; Department of Pharmacy, University of Washington, Seattle (Dr Veenstra).

RELATED ARTICLE

November 14, 2001
JAMA. 2001;286(18):2337-2338.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Novel CYP2C9 Promoter Variants and Assessment of Their Impact on Gene Expression
Kramer et al.
Mol. Pharmacol. 2008;73:1751-1760.
ABSTRACT | FULL TEXT  

TPMT testing in rheumatology: any better than routine monitoring?
Payne et al.
Rheumatology (Oxford) 2007;46:727-729.
FULL TEXT  

Identifying drugs needing pharmacogenetic monitoring in a Korean hospital
Kim et al.
Am J Health Syst Pharm 2007;64:166-175.
ABSTRACT | FULL TEXT  

Pharmacogenetics as Alien Science: Alzheimer's Disease, Core Sets and Expectations
Hedgecoe
Social Studies of Science 2006;36:723-752.
ABSTRACT  

The Intersection Of Biotechnology And Pharmacogenomics: Health Policy Implications
Phillips
Health Aff (Millwood) 2006;25:1271-1280.
ABSTRACT | FULL TEXT  

Genetic testing in cancer therapeutics.
Ezzeldin and Diasio
Clin. Cancer Res. 2006;12:4137-4141.
FULL TEXT  

Metabolism of Efavirenz and 8-Hydroxyefavirenz by P450 2B6 Leads to Inactivation by Two Distinct Mechanisms
Bumpus et al.
J. Pharmacol. Exp. Ther. 2006;318:345-351.
ABSTRACT | FULL TEXT  

Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine
McDowell et al.
BMJ 2006;332:1177-1181.
ABSTRACT | FULL TEXT  

Role of CYP2E1 Immunoglobulin G4 Subclass Antibodies and Complement in Pathogenesis of Idiosyncratic Drug-Induced Hepatitis
Njoku et al.
CVI 2006;13:258-265.
ABSTRACT | FULL TEXT  

In vitro and In vivo Clinical Pharmacology of Dimethyl Benzoylphenylurea, a Novel Oral Tubulin-Interactive Agent
Rudek et al.
Clin. Cancer Res. 2005;11:8503-8511.
ABSTRACT | FULL TEXT  

Pharmacogenetics/genomics and personalized medicine
Sadee and Dai
Hum Mol Genet 2005;14:R207-R214.
ABSTRACT | FULL TEXT  

Pharmacogenetics of outcome in children with acute lymphoblastic leukemia
Rocha et al.
Blood 2005;105:4752-4758.
ABSTRACT | FULL TEXT  

Pharmacogenomics: Harbinger for the Era of Personalized Medicine?
Sadee
Mol. Interv. 2005;5:140-143.
FULL TEXT  

Sequence variation in G-protein-coupled receptors: analysis of single nucleotide polymorphisms
Balasubramanian et al.
Nucleic Acids Res 2005;33:1710-1721.
ABSTRACT | FULL TEXT  

Genes and the Response to Drugs
Caraco
NEJM 2004;351:2867-2869.
FULL TEXT  

Technology And The Boundaries Of The Hospital: Three Emerging Technologies
Goldsmith
Health Aff (Millwood) 2004;23:149-156.
ABSTRACT | FULL TEXT  

Criteria influencing the clinical uptake of pharmacogenomic strategies
Shah
BMJ 2004;328:1482-1486.
FULL TEXT  

Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions
Bellosta et al.
Circulation 2004;109:III-50-III-57.
ABSTRACT | FULL TEXT  

The Clinical Relevance of Genomic Variation
Kansagra and List
JAMA 2004;291:1641-1641.
FULL TEXT  

Racial Meanings and Scientific Methods: Changing Policies for NIH-Sponsored Publications Reporting Human Variation
Stevens
Journal of Health Politics, Policy and Law 2003;28:1033-1088.
ABSTRACT  

Improving medication safety: the measurement conundrum and where to start
Classen and Metzger
Int J Qual Health Care 2003;15:i41-47.
ABSTRACT | FULL TEXT  

Polymorphisms and the Pocketbook: The Cost-Effectiveness of Cytochrome P450 2C19 Genotyping in the Eradication of Helicobacter pylori Infection Associated with Duodenal Ulcer
Lehmann et al.
J Clin Pharmacol 2003;43:1316-1323.
ABSTRACT | FULL TEXT  

A mouse-based strategy for cyclophosphamide pharmacogenomic discovery
Watters et al.
J. Appl. Physiol. 2003;95:1352-1360.
ABSTRACT | FULL TEXT  

Genetic Polymorphism of CYP1A2 in Ethiopians Affecting Induction and Expression: Characterization of Novel Haplotypes with Single-Nucleotide Polymorphisms in Intron 1
Aklillu et al.
Mol. Pharmacol. 2003;64:659-669.
ABSTRACT | FULL TEXT  

Drug-Induced Hepatotoxicity
Lee
NEJM 2003;349:474-485.
FULL TEXT  

The Drugs Don't Work: Expectations and the Shaping of Pharmacogenetics
Hedgecoe and Martin
Social Studies of Science 2003;33:327-364.
ABSTRACT  

Pharmacogenomics: marshalling the human genome to individualise drug therapy
Evans
Gut 2003;52:ii10-18.
ABSTRACT | FULL TEXT  

Pharmacogenomic can give children safer medicines
Impicciatore
Arch. Dis. Child. 2003;88:366-366.
FULL TEXT  

Medication Safety: Moving From Illusion to Reality
Classen
JAMA 2003;289:1154-1156.
FULL TEXT  

Cardiovascular Pharmacogenomics: Current Status, Future Prospects
Anderson et al.
J CARDIOVASC PHARMACOL THER 2003;8:71-83.
ABSTRACT  

Single base extension (SBE) with proofreading polymerases and phosphorothioate primers: improved fidelity in single-substrate assays
Di Giusto and King
Nucleic Acids Res 2003;31:e7-e7.
ABSTRACT | FULL TEXT  

Genetics 101: detecting mutations in human genes
Sinclair
CMAJ 2002;167:275-279.
FULL TEXT  

Pharmacogenetic Challenges For The Health Care System
Robertson et al.
Health Aff (Millwood) 2002;21:155-167.
ABSTRACT | FULL TEXT  

Cochrane Corner
Hachinski
Stroke 2002;33:1739-1739.
FULL TEXT  

Association Between CYP2C9 Genetic Variants and Anticoagulation-Related Outcomes During Warfarin Therapy
Higashi et al.
JAMA 2002;287:1690-1698.
ABSTRACT | FULL TEXT  

Chemokines and Transplant Immunobiology
Hancock
J. Am. Soc. Nephrol. 2002;13:821-824.
FULL TEXT  

Genetics Moves Into the Medical Mainstream
Collins and Guttmacher
JAMA 2001;286:2322-2324.
FULL TEXT